RxDoctor Payments Data

Yasir Jassam

Neurology · Newport Beach, CANPI 1508154428

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $179,360 of the $259,790 with a category attached, or 69.0%. 17 manufacturers reported payments, led by Amgen at 32.5% of the total. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$259,790in general payments, 2019–2025

Across 405 payments — averaging $641.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$85K
  • AstraZeneca$63K
  • Biogen$43K
  • TG Therapeutics, Inc.$22K
  • EMD Serono, Inc.$12K
  • Sanofi$11K
  • plus $25K from 11 others
$325,807in research payments, 2019–2025

Across 31 payments — averaging $10,510 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$178K
  • Sanofi$78K
  • Genentech, Inc.$59K
  • TG Therapeutics, Inc.$10K

What the payments were for

  • Consulting fees$58,29822%
  • Speaking & faculty fees$179,36069%
  • Travel & lodging$12,9305%
  • Food & beverage$8,8603%
  • Education$3430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)137$84,508
AstraZeneca(2 entities)40$62,943
Biogen39$43,068
TG Therapeutics, Inc.25$22,233
EMD Serono, Inc.20$11,671
Sanofi8$10,790
UCB, Inc.6$7,101
Genentech USA, Inc.11$5,276
Argenx US, Inc.6$3,782
Novartis78$3,466
Johnson & Johnson12$3,069
Janssen Global Services, LLC1$1,320
AbbVie(2 entities)17$419
Roche Products Limited1$85
E.r. Squibb & Sons, L.L.C.2$30
Vanda Pharmaceuticals Inc.1$15
Neuropace, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$259,790 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024
$91,137
Medicare patients
228
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate40$244,920
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$191,968
Kesimpta PenOfatumumab11$111,561
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$94,714
GlatopaGlatiramer Acetate17$32,722
Dalfampridine ErDalfampridine36$14,625
Pyridostigmine Bromide73$4,648
Baclofen61$2,213
Gabapentin43$1,287
Carbidopa-LevodopaCarbidopa/Levodopa25$855
Duloxetine Hcl16$711
Memantine Hcl21$641
Prednisone69$507
Famotidine14$195
Propranolol Hcl12$138

Paid to pharmacies, not to this prescriber.

Other neurology in Newport Beach

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →